Unjoni Ewropea - Malti - EMA (European Medicines Agency)

vaia s.a. - pioglitazone hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - pioglitazone huwa indikat bħala t-tieni jew tat - tielet linja tal-it-trattament tad-dijabete tat-tip 2 mellitus kif deskritt hawn taħt:bħala monoterapija:f'pazjenti adulti (speċjalment pażjenti b'piż żejjed) li mhumiex ikkontrollati biżżejjed bid-dieta u l-eżerċizzju li għalihom metformin mhux adattat minħabba kontra-indikazzjonijiet jew intolleranza;bħala terapija dupliċi orali flimkien mal:metformin, f'pazjenti adulti (speċjalment pażjenti b'piż żejjed) b'kontroll gliċemiku insuffiċjenti minkejja l-ogħla doża ttollerata ta ' monoterapija b'metformin;sulfonilurea biss fl-adulti pazjenti li juru intolleranza għal metformina jew li għalihom il-metformin huwa kontra-indikat, b'kontroll gliċemiku insuffiċjenti minkejja l-ogħla doża ttollerata ta 'monoterapija b'sulphonylurea;bħala terapija trippla orali f'kombinazzjoni ma': metformin u mediċina tat-tip sulphonylurea, f'pazjenti adulti (speċjalment pażjenti b'piż żejjed) b'kontroll gliċemiku insuffiċjenti minkejja terapija doppja mill-ħalq. pioglitazone huwa indikat ukoll għall-użu flimkien ma ' l-insulina tat-tip-2-dijabete mellitus f'pazjenti adulti b'kontroll gliċemiku insuffiċjenti bl-insulina u li għalihom metformin mhux adattat minħabba kontra-indikazzjonijiet jew intolleranza (ara sezzjoni 4. wara l-bidu tat-terapija b'pioglitazone, il-pazjenti għandhom jiġu riveduti wara tlieta sa sitt xhur biex tevalwa l-adegwatezza tal-rispons għall-kura (e. it-tnaqqis fl-hba1c). f'pazjenti li jonqsu li juru rispons adegwat, pioglitazone għandu jitwaqqaf. fid-dawl tar-riskji potenzjali fit-tul mal-terapija, it-tobba għandhom jikkonfermaw fil-sussegwenti ta 'rutina reviżjonijiet li l-benefiċċju ta' pioglitazone huwa miżmum (ara sezzjoni 4.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

takeda pharma a/s - metformin hydrochloride, pioglitazone hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - glubrava huwa indikat bħala kura tat-tieni linja ta 'pazjenti adulti tat-tip-2-diabetes-mellitus, speċjalment pazjenti b'piż żejjed, li ma jistgħux jiksbu kontroll glikimiku suffiċjenti bid-doża massima ttollerata ta' metformin orali waħdu. wara l-bidu tat-terapija b'pioglitazone, il-pazjenti għandhom jiġu riveduti wara tlieta sa sitt xhur biex tevalwa l-adegwatezza tal-rispons għall-kura (e. it-tnaqqis fl-hba1c). f'pazjenti li jonqsu li juru rispons adegwat, pioglitazone għandu jitwaqqaf. fid-dawl tar-riskji potenzjali fit-tul mal-terapija, it-tobba għandhom jikkonfermaw fil-sussegwenti ta 'rutina reviżjonijiet li l-benefiċċju ta' pioglitazone jinżamm.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

krka, d.d., novo mesto - pioglitazone hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - pioglitazone huwa indikat bħala t-tieni jew it-tielet linja tal-it-trattament tad-dijabete tat-tip 2 mellitus kif deskritt hawn taħt:kif monotherapyin pazjenti adulti (speċjalment pażjenti b'piż żejjed) li mhumiex ikkontrollati biżżejjed bid-dieta u l-eżerċizzju li għalihom metformin mhux adattat minħabba kontra-indikazzjonijiet jew intolleranza;bħala terapija dupliċi orali flimkien withmetformin, f'pazjenti adulti (speċjalment pażjenti b'piż żejjed) b'kontroll gliċemiku insuffiċjenti minkejja l-ogħla doża ttollerata ta ' monoterapija b'metformin;sulfonilurea biss fl-adulti pazjenti li juru intolleranza għal metformina jew li għalihom il-metformin huwa kontra-indikat, b'kontroll gliċemiku insuffiċjenti minkejja l-ogħla doża ttollerata ta ' monoterapija b'sulphonylurea;bħala terapija trippla orali f'kombinazzjoni withmetformin u mediċina tat-tip sulphonylurea, f'pazjenti adulti (speċjalment pażjenti b'piż żejjed) b'kontroll gliċemiku insuffiċjenti minkejja terapija doppja mill-ħalq. pioglitazone huwa indikat ukoll għall-użu flimkien ma ' insulina fil-dijabete tat-tip 2 mellitus f'pazjenti adulti b'kontroll gliċemiku insuffiċjenti bl-insulina u li għalihom metformin mhux adattat minħabba kontra-indikazzjonijiet jew intolleranza. wara l-bidu tat-terapija b'pioglitazone, il-pazjenti għandhom jiġu riveduti wara 3 sa 6 xhur biex tevalwa l-adegwatezza tal-rispons għall-kura (e. it-tnaqqis fl-hba1c). f'pazjenti li jonqsu li juru rispons adegwat, pioglitazone għandu jitwaqqaf. fid-dawl tar-riskji potenzjali fit-tul mal-terapija, it-tobba għandhom jikkonfermaw fil-sussegwenti ta 'rutina reviżjonijiet li l-benefiċċju ta' pioglitazone jinżamm.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

krka, d.d., novo mesto - pioglitazone hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - pioglitazone huwa indikat bħala t-tieni jew it-tielet linja tal-it-trattament tad-dijabete tat-tip 2 mellitus kif deskritt hawn taħt: bħala monotherapija - fil-pazjenti adulti (speċjalment pażjenti b'piż żejjed) li mhumiex ikkontrollati biżżejjed bid-dieta u l-eżerċizzju li għalihom metformin mhux adattat minħabba kontra-indikazzjonijiet jew intolleranza;bħala terapija dupliċi orali flimkien mal - mediċina tat-tip sulphonylurea, biss f'pazjenti adulti li juru intolleranza għal metformina jew li għalihom il-metformin huwa kontra-indikat, b'kontroll gliċemiku insuffiċjenti minkejja l-ogħla doża ttollerata ta ' monoterapija b'sulphonylurea; pioglitazone huwa indikat ukoll għall-użu flimkien ma ' insulina fil-dijabete tat-tip 2 mellitus f'pazjenti adulti b'kontroll gliċemiku insuffiċjenti bl-insulina u li għalihom metformin mhux adattat minħabba kontra-indikazzjonijiet jew intolleranza. wara l-bidu tat-terapija b'pioglitazone, il-pazjenti għandhom jiġu riveduti wara 3 sa 6 xhur biex tevalwa l-adegwatezza tal-rispons għall-kura (e. it-tnaqqis fl-hba1c). f'pazjenti li jonqsu li juru rispons adegwat, pioglitazone għandu jitwaqqaf. fid-dawl tar-riskji potenzjali fit-tul mal-terapija, it-tobba għandhom jikkonfermaw fil-sussegwenti ta 'rutina reviżjonijiet li l-benefiċċju ta' pioglitazone jinżamm.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

actavis group ptc ehf   - pioglitazone hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - pioglitazone is indicated as second or third line treatment of type 2 diabetes mellitus as described below:as monotherapyin adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance. as dual oral therapy in combination withmetformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin. a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea. as triple oral therapy in combination withmetformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone is also indicated for combination with insulin in type 2 diabetes mellitus adult patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance (see section 4. wara l-bidu tat-terapija b'pioglitazone, il-pazjenti għandhom jiġu riveduti wara 3 sa 6 xhur biex tevalwa l-adegwatezza tal-rispons għall-kura (e. it-tnaqqis fl-hba1c). f'pazjenti li jonqsu li juru rispons adegwat, pioglitazone għandu jitwaqqaf. fid-dawl tar-riskji potenzjali fit-tul mal-terapija, it-tobba għandhom jikkonfermaw fil-sussegwenti ta 'rutina reviżjonijiet li l-benefiċċju ta' pioglitazone huwa miżmum (ara sezzjoni 4.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptin, metformin hydrochloride - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

actavis group ptc ehf    - pioglitazone hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - pioglitazone is indicated as second or third line treatment of type-2 diabetes mellitus as described below:as monotherapy:in adult patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in adult patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in adult patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in adult patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy. pioglitazone huwa indikat ukoll għall-użu flimkien ma ' insulina fil-dijabete tat-tip 2 mellitus f'pazjenti adulti b'kontroll gliċemiku insuffiċjenti bl-insulina u li għalihom metformin mhux adattat minħabba kontra-indikazzjonijiet jew intolleranza. wara l-bidu tat-terapija b'pioglitazone, il-pazjenti għandhom jiġu riveduti wara 3 sa 6 xhur biex tevalwa l-adegwatezza tal-rispons għall-kura (e. it-tnaqqis fl-hba1c). f'pazjenti li jonqsu li juru rispons adegwat, pioglitazone għandu jitwaqqaf. fid-dawl tar-riskji potenzjali fit-tul mal-terapija, it-tobba għandhom jikkonfermaw fil-sussegwenti ta 'rutina reviżjonijiet li l-benefiċċju ta' pioglitazone jinżamm.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - pioglitazone hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - pioglitazone huwa indikat fit-trattament tad-dijabete tat-tip 2 mellitus:kif monotherapyin pazjenti adulti (speċjalment pażjenti b'piż żejjed) li mhumiex ikkontrollati biżżejjed bid-dieta u l-eżerċizzju li għalihom metformin mhux adattat minħabba kontra-indikazzjonijiet jew intolleranza. wara l-bidu tat-terapija b'pioglitazone, il-pazjenti għandhom jiġu riveduti wara 3 sa 6 xhur biex tevalwa l-adegwatezza tal-rispons għall-kura (e. it-tnaqqis fl-hba1c). f'pazjenti li jonqsu li juru rispons adegwat, pioglitazone għandu jitwaqqaf. fid-dawl tar-riskji potenzjali fit-tul mal-terapija, it-tobba għandhom jikkonfermaw fil-sussegwenti ta 'rutina reviżjonijiet li l-benefiċċju ta' pioglitazone jinżamm.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited  - vildagliptin, metformin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - zomarist is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

cheplapharm arzneimittel gmbh - pioglitazone, metformin hydrochloride - diabetes mellitus, tip 2 - drogi użati fid-dijabete - competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.